2015 Advocacy Efforts

November 30, 2016


October 2015

Moderated afternoon session of Rep. Susan W. Brooks, “Connecting Classrooms and Careers” program.

September 2015

Signed on to a joint letter to the President urging him to focus on ag biotech issues in his upcoming meetings with President Xi Jinping of China.

August 2015

Participated with IMDMC in Legislative Roundtable, Indianapolis

July 2015

Participated in Hoosiers Work for Health/We Work for Health PhRMA Partnership Fly-In to Washington D.C.

June 2015

Requested Indiana Congressional Delegation to sign-on to bi-partisan letter encouraging fair and balanced patent reform consideration in HR 9.

Met with Rep. Susan W. Brooks at BIO Convention in Philadelphia, provided tour of Indiana booth in the conference exhibit hall

May 2015

Awarded Rep. Susan W. Brooks IHIF’s Legislator of the Year Award for outstanding service to Indiana’s health science sector

Signed on to joint-association letter supporting H.R. 1078, the FDA Safety Over Sequestration (SOS) Act

Participated in Hoosiers Work for Health Award to Rep. Susan W. Brooks

Signed on to Healthcare Leadership Forum letter to repeal IPAB

April 2015

Participated in the BIO Fly-In to Washington, D.C. – met with nine of Indiana’s eleven offices.

March 2015

Signed on to the Declaration Supporting Incentives for Medical Innovation in Trade Agreements organized by the Global Colon Cancer Association and the Information Technology and Innovation Foundation

February 2015

Indiana Expanding Exports and Creating Jobs – Fact Sheet with information on TTIP and TPA impacts on state.

Signed on to National Osteoporosis Foundation letter to Congress supporting Medicare Part D.

January 2015

IHF signed on to a letter to the Administration emphasizing the importance of strong IP and data protections for medicines.  Letter was initiated by the Global Colon Cancer Association and the Information Technology and Innovation Foundation.

IHIF co-hosted our 4th Annual Legislative Breakfast Briefing (agenda) on January 28th.  Co-Hosts include IMDMC and Hoosiers Work for Health/PhRMA

IHIF shared concerns over Senator Elizabeth Warren’s “Medical Innovation Act”.

IHIF provided informational testimony on HB 1065 – Use of investigational drugs, biologics, and devices.  Also expressed concern over SB 66.

IHIF signs on to letter encouraging US legislators to proceed with caution when considering making changes to patent legislation

IHIF signs on to letter to US legislators highlighting the success of Medicare Part D and urging Congress to reject any proposals that would undermine the current program’s success in holding down premiums and taxpayer costs, while still producing high satisfaction rates among enrollees.

2016 Advocacy Efforts

November 30, 2016

Recent Activities

October 2016

Signed on to letter  sponsored by the Healthcare Leadership Council in support of repeal of IPAB.

August 2016

Signed on to letter supporting intellectual property protections in current UN negotiations.

Signed on to BIO letter to SEC supporting re-examination of the definition of ‘Smaller Reporting Companies”.

June 2016

IHIF supports HWFH and opposition to Medicare Part B Demo

May 2016 

IHIF joins BIO and other state bioscience groups in supporting the Fostering Innovation Act – allowing growing bioscience companies to focus on R&D.  Read BIO’s statement on passage of the Act here

IHIF announces Legislators of the Year at 2016 Annual Meeting – Honoring Rep. Larry Bucshon, M.D. and Senator Patricia Miller

April 2016

IHIF attends BIO Fly-In to meet with entire Indiana federal delegation in Washington, D.C. – continuing focus on Medicare Part B reimbursement changes.

March 2016

Provided Letter of Support for HB 3320 – A Bill to Establish a Smart Card Pilot Program Under Medicare

Participated in Lilly 2016 Vendor Conference

Signed on to letter opposing CMS proposed changes to Medicare Part B

January 2016

IHIF testified in favor of HB 1176 – creating a Diabetes Incidence Study and Action Plan through IDOH.  The bill was held and DOH was requested to provide a study update to stakeholders within six months.

IHIF Legislative Breakfast featuring remarks by Rep. Ed Clere and Lt. Governor Sue Ellspermann.

Activity Archive


ShareVault Webinar – October 13, 2016

October 7, 2016


ShareVault Webinar – “Must-Know Finance Concepts for Life Sciences Valuations Part 2:  A More Detailed Explanation of Concepts”

Thursday, October 13, 2016, 11am-12pm PST / 2pm-3pm EST

Speakers:  John Selig & Jeff Karan, Managing Partners, Mavericks Capital

This webinar is a continuation of the first webinar, entitled “Must-Know Finance Concepts for Life Sciences Valuations,” and goes into more detail on the key concepts and most common methodologies used to evaluate life sciences assets.

Questions answered in Part 2 include:

  • Which asset valuation methodology is most used by big pharma to evaluate possible partners or acquisitions?
  • An explanation of three fundamental concepts in valuation: risk-adjusted value, cost of capital and present value
  • What are some cash flow examples for a situation when the asset is early in the product lifecycle, for out-licensed, and for in-licensed products?
  • How do my expected deal terms relate to my forecast cash flows? How can I use this to make better decisions on licensing timing?

And more.

If you are an entrepreneur who plans to raise (or currently is raising) financing, licensing an asset or selling your company, a private investor who wants to estimate and negotiate start-up share value, or any other professional who is active in the life sciences investing sector, you’ll benefit from this more detailed explanation of life sciences valuation methodologies.

At the end of their presentation, the speakers will respond to questions from the audience.

Click here to learn more and register:  http://bit.ly/2dtz5tN

Moonshot for Pediatric Pharmacology

August 30, 2016

By: Peter T. Kissinger

*Published in August 2016 issue of Drug Discovery News and Op/Ed section of the Indianapolis Business Journal Aug. 29 edition     

Fire up the rocket. This month I hope to stimulate debate in favor of an underrepresented group in clinical pharmacology research.  Two decades ago women were underrepresented, including even female rats.   We’ve made real progress. The same is true for the elderly and racial minorities, although that challenge continues, as reflected in the FDA declaring 2016 the Year of Diversity in Clinical Trials.


Children remain a group neglected by the pharmaceutical industry.  They are a vulnerable and inconvenient population for medical research, especially outside the developed economies.  This is a demographic which demands an individualized approach to therapy that is even more compelling than for adults.  Many children die of infectious diseases and malnutrition while others are permanently damaged.  Others have inborn metabolic errors which respond well when caught early. Children, of course, contract cancer.  Physicians often must guess on drug choice and dose, because there is limited supporting data and often no suitable formulation.  Mixing portions of drugs with compatible (or not) “baby food” is common for parents and not well controlled.  Adult formulations are often unsuitable for children in physical size, dose, and excipients. Special pediatric formulations, such as liquids, require extensive regulatory review, including oral syringes for parents to use, which are then medical devices.

Self-administered protein-based drugs become more popular for adults, for example, using pumps.  In children this presents costly regulatory issues with labeling, instructions and compatibility with little hands and physical play.

There is opportunity, step-by-step to now reduce the art and increase the science.  Pharmacophenomic progress can be made today, without any speculative drug discovery.  Most approved drugs compatible with pediatric disease are generic, but few have been thoroughly studied in children as N=1 individuals.   The goal of individualized, data-based dosing for children also has implications for adults. The current government precision medicine initiative is largely genetics focused and does not explicitly deal with the phenotypic reality of individuals. The likelihood of genomics solving many diagnostics challenges is very small.  It is only one dimension of a multifactorial problem for which we have many new tools.


Why are children not the focus of clinical pharmacology?


  1. Children are not small adults.  Their phenotype changes very rapidly from birth to their early 20s. This is inconvenient for scientists and statisticians alike.
  2. Children are generally healthy and thus represent a small market for new drugs. This is inconvenient for CFOs.
  3. The ethical challenges of clinical trials with children are daunting to some. Informed consent is for parents/guardians. We do not do drug trials on healthy children as we typically do for adults (Phase I).  On the other hand, adult trials will have been done first. Recruiting sufficient numbers of patients for statistical power is tough, but with better measurements you need fewer subjects.
  4. The rate of change in children confounds clinical trials of any length. For example, newborns vary biochemically month to month.  Age is NOT a good metric for measured phenotype. The equivalent of a three year trial for patients in their 40s is impossible in patients who will double in age over 3 years.
  5. While Congress and the FDA have provided incentives (extended market exclusivity) to pharmaceutical companies who add a pediatric component to trials for new drugs, the incentive is not often sufficiently compelling. There are many generic drugs that are useful in children, but most have not yet been studied in children using modern protocols before patents have expired.
  6. Young children are small. Neonates are tiny.  This makes both physical and chemical measurements more difficult than for adults. Small blood volumes is one challenge. Children also do not have the mobility to get to a clinic on their own and most can’t describe their feelings with any precision to a caregiver as researcher.
  7. Because of the “tyranny of averages” from clinical trials and the significant variations in the rate of ontogeny person-to-person, children are especially subject to medical errors of drug choice and dose. Dosing in units of mg/kg of body weight is done because it is better than nothing, not because it optimizes a satisfactory result.  It does not!



There are good things to say about pediatric research.


  1. The return on investment in children’s health promises to be much higher than the return on investment in the health of elderly professors like me. Preventive medicine means a lot.
  2. Children as a rule have avoided some of the bad habits that make studies in adults inconvenient (smoking, alcoholism, drug addiction, French fries,…) and have not experienced the degenerative diseases of aging.
  3. Children are less subject to polypharmacy and thus have fewer drug-drug interactions or drug induced enzymes.


To facilitate research, we are moving step-by-step from accumulated “art” to evidence-based medicine (decisions by averages from randomized trials) and on now to individualized medicine based on N=1 data.  While physics plays a role, chemistry is more specific in health care research.  My own team has developed means of automatically sampling exquisitely small blood volumes in a preprogrammed painless way that eliminates labor and reduces infection risk.  This is especially important with respect to recruiting children for trials where parental approval is crucial.  Colleagues have further developed measurement technologies that are compatible with much smaller sample volumes than even a decade ago. These include several ambient ionization mass spectrometry schemes, among others.   Today the required sample volumes and concentrations for quality measurements are both reduced by up to a million-fold compared to 1980.   Expertise in modelling and predicting, much of it developed from industrial engineering, is now coming into play.  Health care is a process that is largely “out of control” because of inadequate process monitoring along the way.  Proper decisions by health care providers are thus inhibited.  Imagine operating a chemical, electronics or auto plant with such haphazard in-process monitoring.


Nutrition matters because food-effects matter and the microbiome also impacts circulating drug concentrations.  Today these are not adequately measured in children.  Some data will improve decision making.  Better, faster, cheaper data will improve decision making more.  A malnourished child in Africa will not react to a drug the way a plump over-nourished child in Indiana will.


Collaborative Opportunities:


There are several networks of Children’s Hospitals, many of which have a research component. The NIH (NICHD) has organized a pediatric trials network (PTN) and a neonatal research network (NRN) among children’s hospitals that share experiences and data. [Taken from the NICHD website: “Formed in 1986, the NICHD Neonatal Research Network (NRN) is a collaborative network of neonatal intensive care units across the United States. The NRN comprises 18 clinical centers.”  “The main objective of the PTN is to provide an environment and an appropriate infrastructure for conducting safe and effective pediatric clinical trials for the Best Pharmaceuticals for Children Act (BPCA) drug development program and for performing ancillary activities in support of these trials. The network will conduct pediatric clinical drug trials in a variety of therapeutic areas, including but not limited to cardiovascular diseases, cancer, infectious diseases, gastroenterology, respiratory diseases, neonatology, and medical devices.”]  I encourage those working in drug discovery to consider pediatric applications early and often. Please also recall that many drugs used in this population were approved before the new tools became available.  When you consider estate planning, consider pediatric pharmacology. After all, government contribution to R/D is far below traditions in % of the federal budget and as a % of GDP.  The kids will be unaware of this until they are 30.  Let’s lend them a hand now to reduce the cost of the downstream consequences of inadequate care.


[Note:  On July 14, The Research to Accelerate Cures and Equity (RACE) for Children Act was introduced to Congress requiring compliance with the Pediatric Research Equity Act (PREA) of 2003.  This no doubt will be debated for quite some time. Alert readers will note that the word compliance almost always implies longer R/D cycles, higher drug prices and less venture investing in research.  Of course, RACE would not stimulate the optimization of generic drug use in children as described above.]



IHIF is a Proud Partner in National Health IT Week

August 21, 2016

This September, IHIF — as a partner in the advancement of health information technology to help improve healthcare —is a Proud Partner in National Health IT Week.  National Health IT Week is the premier event offering all healthcare stakeholders an opportunity to unite under one banner, expressing the benefits that health information technology (IT) brings to U.S. healthcare. “The Value of Health IT.”

Comprehensive health care reform is not possible without system-wide adoption of health information technology, which improves the quality of healthcare delivery, increases patient safety, decreases medical errors, and strengthens the interaction between patients and healthcare providers.

With Meaningful Use now providing the way forward, eligible providers across the country increasingly understand the benefits for themselves and their patients, and are adopting Meaningful Use compliant electronic health records.

Initiated in 2006 by the Healthcare Information and Management Systems Society (HIMSS), National Health IT Week has emerged as a landmark occasion for using health IT as part of the overall solution to improve America’s healthcare as a bipartisan, federally led, market driven initiative.

The Week consists of events across the country, including National Health IT Weekparticipants —vendors, provider organizations, payers, pharmaceutical/biotech companies, government agencies, industry/professional associations, research foundations, and consumer protection groups— all working together to elevate national attention to the advantages of advancing health IT.

View our full list of partners and updates on the Week’s events. Working together with our growing coalition of stakeholders, IHIF is helping to transform healthcare for all.

Deadlines to Apply for NCATS Funding Opportunities are Coming Up September 6!

August 21, 2016

This is a reminder that the National Center for Advancing Translational Sciences (NCATS) has several open Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) program funding opportunities designed to help advance and commercialize translational research technologies. NCATS encourages applications in these four research areas of interest: drug discovery and development, diagnostics and devices, bioinformatics and information technology, and clinical research.


All opportunities below have an application deadline of Sept. 6, 2016, 5 p.m. local time.


2016 Omnibus Solicitation

Small businesses, research and technology transfer organizations are eligible to apply for the 2016 Omnibus Solicitation. Applications may address any stage of translation, from target validation through pre-clinical and clinical evaluation to intervention, implementation and dissemination. Review NCATS’ research priorities to determine its areas of interest.

Other Funding Opportunities

SBIR Direct Phase II

Small businesses that have accomplished the objectives of a Phase I SBIR grant through non-SBIR funds are able to apply for SBIR direct-to-Phase II funding. Applicants must demonstrate the scientific and technical merit and feasibility of the prototype stage of developing a biomedical technology that has commercial potential.

  • PAR-15-288: Direct Phase II SBIR Grants to Support Extended Development, Hardening, and Dissemination of Technologies in Biomedical Computing, Informatics, and Big Data Science
  • PAR-14-088: Direct Phase II SBIR Grants to Support Biomedical Technology Development


SBIR Technology Transfer

This funding opportunity encourages SBIR grant applications from small business concerns for projects to transfer technology out of the NIH intramural research labs into the private sector.

  • PA-15-354: SBIR Technology Transfer (R43/R44)


Platform Delivery Technologies for Nucleic Acid Therapeutics

This funding opportunity is designed to incentivize small businesses to generate new technologies and products for delivering nucleic acids into cells and tissues for the purpose of treatment or prevention of human disease.

  • PA-14-307: Platform Delivery Technologies for Nucleic Acid Therapeutics (R43/R44)
  • PA-14-308: Platform Delivery Technologies for Nucleic Acid Therapeutics (R41/R42)


Development of Appropriate Pediatric Formulations and Drug Delivery Systems

Applications must address different and complementary research needs for the development of appropriate pediatric drug formulations in different age groups.

  • PAR-13-345: Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R43)
  • PAR-13-346: Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R41)


Learn more about current funding opportunities for small business at NCATS Small Business, including eligibility requirements and research priorities. Need help? Contact NCATS SBIR and STTR to discuss your project idea.


Connect with NCATS! Like us on Facebook and follow us on Twitter. Use #NCATSsbir and join the online conversation.



NCATS’ SBIR and STTR programs are engines of innovation for developing and commercializing tools, technologies and intervention platforms to support the creation of new therapeutics and diagnostics. SBIR and STTR are government set-aside programs for domestic small businesses to engage in research and development that has the potential for commercialization and public benefit.

Ivy Tech Bloomington led development of national educational skill standard for medical device careers

August 9, 2016



August 9, 2016


Contact:  Amanda Billings

Executive Director, Marketing/Communications

Ivy Tech Community College – Bloomington

(812) 330-6222   |   abillings7@ivytech.edu


BLOOMINGTON – Ivy Tech Community College’s Bloomington campus led a consortium of 12 other community colleges and 72 medical device industry partners nationwide to develop the nation’s first skill set standards for entry-level medical device jobs in the U.S. The Community College Consortium for Bioscience Credentials (c3bc) published “Medical Device Skill Standards,” a manual of educational guidelines to ensure educators and trainers develop and teach the skills needed in entry level medical device jobs in the U.S. The project was funded by a $15 million dollar grant from the U.S. Department of Labor.


Sengyong Lee, Ph.D., professor and Ivy Tech Bloomington biotechnology program chair, is c3bc’s medical device hub leader. Dr. Lee and his team at Ivy Tech Bloomington led the nationwide collaboration. “The advancement of medical technology and growing health care needs for elderly populations around the globe have accelerated the growth of companies like Cook Medical in recent decades,” Dr. Lee said. “The medical device industry is in need of a continuous pipeline of skilled workers to meet their growth demands. Our partners and educators who developed the skill standards manual hope for a long-term return on investment in the form of graduates from community colleges who will fill those jobs.”


Local employers, including Chapman Lake Instrument Corp., Cook Medical, Cook Polymer Technology, and Boston Scientific Corporation, participated as industry partners. Employers outlined skills needed in entry-level medical device positions, which educators used to create skill standards for teaching and testing students.


Educators nationwide have already begun to use the skill standards manual to create new and revise educational courses, certificates, and degrees to align with industry needs. For example, Ivy Tech Bloomington developed a new medical device quality certificate that counts toward the biotechnology associate degree and leads to a career in the industry. Ivy Tech Bloomington also has a plastics program and regulatory affairs certificate to meet local employer needs.


In addition to publishing the manual, c3bc also developed ‘Courses in a Box’ which educators nationwide can use to develop curriculum. The downloadable, digital materials outline exactly what should be taught, and includes everything a credentialed instructor would need to teach the course online or in person.


“The courses in a box project will be especially valuable to educators and trainers who are new in the field. Of course, the main beneficiaries of the project are the students and trainees who will receive valuable education,” Dr. Lee said.


The c3bc’s Medical Device Skill Standards manual and Courses in a Box are now published and are free and available to download. The standards manual can be found online at

https://www.skillscommons.org/handle/taaccct/8777 and the Courses in a Box can be found at



For information about Bloomington programs in medical device manufacturing, plastics, and biotechnology, visit ivytech.edu/biotechnology and click Bloomington. Fall classes begin August 22 but students should enroll by August 12 in order to be prepared on the first day of classes. To enroll, visit www.ivytech.edu/applynow, stop into Ivy Tech Bloomington located at 200 Daniels Way, or call (812) 330-6013.


About Ivy Tech Community College
Ivy Tech Community College (www.ivytech.edu) is the state’s largest public postsecondary institution and the nation’s largest singly accredited statewide community college system.  Ivy Tech has campuses throughout Indiana. It serves as the state’s engine of workforce development, offering affordable degree programs and training that are aligned with the needs of its community along with courses and programs that transfer to other colleges and universities in Indiana. It is accredited by the Higher Learning Commission and a member of the North Central Association.




Interview contacts:


Dr. Sengyong Lee



Chris Kilander

Global Product Manager/Team Leader – Peripheral Intervention

Cook Incorporated

750 Daniels Way

Bloomington, IN 47404

1-800-468-1379 ext. 10-1978

Mobile: 812-322-8097



Kathy Heuer,

Executive Director, Indiana Medical Device Manufacturing Council, Inc.

Kathy Heuer

Executive Director, IMDMC, Inc.

PO Box 441385

Indianapolis, IN 46244

(260) 609-2802



NCI FY2017 Contract Topics Now Available

August 3, 2016

FY2017 Contract Topics Now Available!

The National Cancer Institute Small Business Innovation Research (NCI SBIR) Development Center funding opportunities come in two large categories: grants and contracts. Contracts are legally binding agreement for the direct use or benefit of the Government, and involve deliverables at the end. This year, there are 15 contract topics in high priority research areas ranging from therapeutics to digital health. See below or visit our website to find out more about this year’s topics. Proposals are due by October 21, 2016, 5:00 PM EDT.  Please direct all questions regarding contracts to the NCI Office of Acquisitions (ncioasbir@mail.nih.gov).




August 24, 2016, 2:00 PM EDT


The session will cover:
PHS2017-1 Solicitation
Contract Topics per IC
Electronic Contract Proposal Submission (eCPS) Website

For more information about the NCI SBIR & STTR Programs, please visit the website.

The SBIR & STTR Programs are NCI’s engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer. The SBIR & STTR Programs are government set-aside programs for domestic small businesses to engage in research and development that has the potential for commercialization and public benefit.

Sign up to receive updates about SBIR & STTR funding opportunities at sbir.cancer.gov.


IHIF Welcomes New Members

August 3, 2016

Quality Connection

Quality Connection is a labor management partnership comprised of 100 union electrical contractors and nearly 3,000 International Brotherhood of Electrical Workers (IBEW) #481 electrical workers. Together labor and management provide the needed expertise, highly trained workforce, safety and dedication to help build many of Central Indiana’s premiere education, health care, utility sites and logistics projects. The unique business relationship spans more than 50 years and represents a strong tradition of quality electrical construction, progressive labor negotiations and community service. With an unprecedented commitment to workforce training, job safety and worker standards. Quality Connection . . .Quality Work, Customer Connected. Learn more at www.qcindy.com

NeRX Biosciences

One of the most effective chemotherapeutics used in the treatment of cancer continues to be the DNA damaging agent cisplatin. Pioneered by our Medical Advisor, Dr. Larry Einhorn at the Indiana University School of Medicine for the treatment of testicular cancer, cure rates now exceed 90% for this cancer. This represents one of the few shining stories since the “War on Cancer” was initiated in the early 1970’s. Unfortunately, cisplatin is considerably less effective in treating other cancers but remain first-line treatment for lung and ovarian cancer. NERx Biosciences co-founder and CSO, Dr. John Turchi has been studying the biology and biochemistry of cisplatin for 25 years and in 2005 was recruited to the Indiana University Cancer Center where advances in his laboratory have paved the way for recapitulating the successes of platinum treatment for testicular cancer in lung and ovarian cancer.

NĒRx Biosciences was established in 2009 to capitalize on these advances and discoveries to develop novel therapeutics to enable the effective treatment of highly prevalent and difficult to treat cancers including lung and ovarian. Learn more at www.nerxbiosciences.com.


Azenix/Futago Corporation

 Researching and developing advanced process technology and design manufacturing plan cooperated with Futago LLC.


KinaSense is developing cell-based assays used in preclinical drug discovery to identify and characeterize new compounds for oncology. Our assays are faster, less expensive, and have more physiological relevance than traditional methods used in target validation and potency studies, allowing earlier decision making fro progressing compounds into animal studies.Learn more at www.kinasense.com.


MorNuCo, Inc. is a biotech company focused on age related diseases with an emphasis on cancer detection. Learn more at www.mornuco.com.

Phytoption LLC

Phytoption LLC is an innovation company developing propriatory ingredients to improve drug bioavailability, food quality, and cosmetics functionality. It offers patented technology and ingredients to pharmaceutical, food, or cosmetic industrial partners.

Safekeeping (2)

Safekeeping is a moblie application that delivers health and lifestyle information to family members of patients in care facilities.Learn more at www.safekeepingapp.com.

July 2016 Lunch Program: Women in Life Science Leadership

July 21, 2016

Tuesday, July 19

Every so often we like to highlight and recognize the success and influence of women in the life science industry.  This year, we focus on how women make the move out of the lab (or its sector equivalent) and into company leadership.  Reflecting a national conversation backed by some rather dismal (but improving!) statistics, we will here from 3-4 entrepreneurs and more seasoned leaders about how women acquire the experience, tools, networks, and investor confidence to take charge of their innovations and lead their companies forward.


Deborah Pollack-Milgate, Partner

Barnes & Thornburg LLP


Kristin Eilenberg, CEO
Lodestone Logic/Lodestone Insights

Terri Pascarelli, CEO
AIT BioScience

Sherry Harbin, Ph.D., CEO
GeniPhys LLC

Margo Enright

The Indiana Health Industry Forum and Barnes & Thornburg LLP partner to present a monthly seminar series on critical issues in life science. Each month, at lunch, a policymaker or a panel in the field of life science will be available to answer questions concerning the major challenges and opportunities in the life science industry. We hope you will join us.

For more information on upcoming programs, please visit www.ihif.org/pages/lifescience

Follow us on Twitter @IHIF1 #LifeScienceLunch @BTLawNews